Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 9.83 as of 2026-10-06T20:08:02.637Z.
Consensus retrieved: 2026-10-06T14:51:05.310Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:08:02.637Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e4cd533ac20a6f80cd606aebe48acc9b54aed9ffabeca25d6b8b689be79c8f7
Forward PE Ratio (9.83) = Dated Quote Price ($8.81) / Consensus Forward EPS ($0.90)
FORWARD PE RATIO
9.83
SECTOR MEDIAN · HEALTHCARE
19.75
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
-50.23%
vs the sector median at left
OptimizeRx Corp.
Market Cap
$165.32M
Forward PE Ratio
9.83
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| OptimizeRx Corp. (OPRX) | $165.32M | 9.83 |
| Nkarta, Inc. (NKTX)vs › | $165.27M | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $168.10M | N/A |
| Quanterix Corporation (QTRX)vs › | $162.04M | N/A |
| MediWound Ltd. (MDWD)vs › | $168.92M | N/A |
| Journey Medical Corporation (DERM)vs › | $169.53M | N/A |
| Minerva Neurosciences, Inc. (NERV)vs › | $159.80M | N/A |
| PepGen Inc. (PEPG)vs › | $159.78M | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $171.13M | N/A |
| LifeMD, Inc. (LFMDP)vs › | $159.22M | N/A |
Trailing P/E
37.7
reported TTM EPS
Forward P/E
9.8
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.90 implies +291.3% EPS growth vs the reported trailing $0.23.
At the dated quote price of $8.81, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.90 | $0.81 – $0.96 | 4 | 9.8x |
| 2027-12-31 | $1.08 | $0.96 – $1.32 | 4 | 8.1x |
| 2028-12-31 | $1.07 | $1.04 – $1.15 | 1 | 8.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
